NCT03998514 - A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 9, 2018

Primary Completion Date

April 19, 2021

Study Completion Date

April 19, 2021

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

DRUG

CB4211 Dose 1

Administered by subcutaneous injection

DRUG

CB4211 Dose 2

Administered by subcutaneous injection

DRUG

CB4211 Dose 3

Administered by subcutaneous injection

DRUG

CB4211 Dose 4

Administered by subcutaneous injection

DRUG

CB4211 Dose 5

Administered by subcutaneous injection

DRUG

CB4211 Dose 6

Administered by subcutaneous injection

DRUG

CB4211 Dose TBD

Administered by subcutaneous injection

DRUG

Placebo

Administered by subcutaneous injection

Trial Locations (4)

75247

Covance Clinical Research Unit Inc., Dallas

78215

The Texas Liver Institute, San Antonio

78229

Endeavor Clinical Trials, LLC, San Antonio

91911

ProScietno, Chula Vista

All Listed Sponsors

lead

CohBar, Inc.

INDUSTRY